Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abbott Submits Architect HE4 Assay For FDA Clearance
The company has partnered with Fujirebio Diagnostics in the development of the assay. The Architect HE4 assay has been approved for use in Europe, as well as in
The company has partnered with Fujirebio Diagnostics in the development of the assay. The Architect HE4 assay has been approved for use in Europe, as well as in
As per the new agreement, Teva has extended its marketing and distribution rights to include the Nordic and Baltic regions, previously held by Active Biotech. Active Biotech is
The Phase 2-3, multi-center, randomised, double-blind, placebo-controlled and international study is expected to evaluate the efficacy and safety of inhaled, human AAT in alpha-1 deficient patients with emphysema.
Reportedly, collaborating with Corgenix and Tulane in the contract are The Scripps Research Institute, the University of California at San Diego, Boston University, the Broad Institute, Harvard University,
Carmot is expected to use the FBLD technology, called ‘Chemotype Evolution,’ for identifying drug candidates in a broad range of therapeutic areas, including inflammatory, metabolic, and neurodegenerative diseases.
The company said that Dr Streeter will relocate to Gainesville, Florida from San Diego, California where he served most recently as the founder and chief scientific officer of
Labetalol is the third product launched under partnership with Strides Arcolab. Under the joint venture partnership, Sagent and Strides Arcolab have been jointly developing, supplying and marketing more
As per terms of the agreement, Safecor Health is expected to provide Premier members a flexible and comprehensive menu of unit-dose and bar-coded repackaging services geared toward each
EHSI said that the term sheet review is a positive step that is necessary to pursue final terms under EHSI’s recent option agreement with ThromboVision, a company that
The study and the ongoing Phase 3 trial in chronic kidney disease patients are directed toward fulfilling licensure requirements in the US, Canada and Europe. Heplisav has been